Back to top

EyePoint completes Phase 3 DURAVYU enrollment for DME

EyePoint Pharmaceuticals ( ($EYPT) ) has provided an announcement. On July 30, 2026, EyePoint announced it had completed enrollment in its pivotal ...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

EyePoint, Inc. (EYPT)